PURPOSE: To investigate the adequacy of three-dimensional (3D) Monte Carlo (MC) optimization (3DMCO) and the potential of four-dimensional (4D) dose renormalization (4DMCrenorm) and optimization (4DMCO) for CyberKnife (Accuray Inc., Sunnyvale, CA) radiotherapy planning in lung cancer. MATERIALS AND METHODS: For 20 lung tumors, 3DMCO and 4DMCO plans were generated with planning target volume (PTV5 mm) = gross tumor volume (GTV) plus 5 mm, assuming 3 mm for tracking errors (PTV3 mm) and 2 mm for residual organ deformations. Three fractions of 60 Gy were prescribed to ≥ 95 % of the PTV5 mm. Each 3DMCO plan was recalculated by 4D MC dose calculation (4DMCrecal) to assess the dosimetric impact of organ deformations. The 4DMCrecal plans were renormalized (4DMCrenorm) to 95 % dose coverage of the PTV5 mm for comparisons with the 4DMCO plans. A 3DMCO plan was considered adequate if the 4DMCrecal plan showed ≥ 95 % of the PTV3 mm receiving 60 Gy and doses to other organs at risk (OARs) were below the limits. RESULTS: In seven lesions, 3DMCO was inadequate, providing < 95 % dose coverage to the PTV3 mm. Comparison of 4DMCrecal and 3DMCO plans showed that organ deformations resulted in lower OAR doses. Renormalizing the 4DMCrecal plans could produce OAR doses higher than the tolerances in some 4DMCrenorm plans. Dose conformity of the 4DMCrenorm plans was inferior to that of the 3DMCO and 4DMCO plans. The 4DMCO plans did not always achieve OAR dose reductions compared to 3DMCO and 4DMCrenorm plans. CONCLUSION: This study indicates that 3DMCO with 2 mm margins for organ deformations may be inadequate for Cyberknife-based lung stereotactic body radiotherapy (SBRT). Renormalizing the 4DMCrecal plans could produce degraded dose conformity and increased OAR doses; 4DMCO can resolve this problem.
PURPOSE: To investigate the adequacy of three-dimensional (3D) Monte Carlo (MC) optimization (3DMCO) and the potential of four-dimensional (4D) dose renormalization (4DMCrenorm) and optimization (4DMCO) for CyberKnife (Accuray Inc., Sunnyvale, CA) radiotherapy planning in lung cancer. MATERIALS AND METHODS: For 20 lung tumors, 3DMCO and 4DMCO plans were generated with planning target volume (PTV5 mm) = gross tumor volume (GTV) plus 5 mm, assuming 3 mm for tracking errors (PTV3 mm) and 2 mm for residual organ deformations. Three fractions of 60 Gy were prescribed to ≥ 95 % of the PTV5 mm. Each 3DMCO plan was recalculated by 4D MC dose calculation (4DMCrecal) to assess the dosimetric impact of organ deformations. The 4DMCrecal plans were renormalized (4DMCrenorm) to 95 % dose coverage of the PTV5 mm for comparisons with the 4DMCO plans. A 3DMCO plan was considered adequate if the 4DMCrecal plan showed ≥ 95 % of the PTV3 mm receiving 60 Gy and doses to other organs at risk (OARs) were below the limits. RESULTS: In seven lesions, 3DMCO was inadequate, providing < 95 % dose coverage to the PTV3 mm. Comparison of 4DMCrecal and 3DMCO plans showed that organ deformations resulted in lower OAR doses. Renormalizing the 4DMCrecal plans could produce OAR doses higher than the tolerances in some 4DMCrenorm plans. Dose conformity of the 4DMCrenorm plans was inferior to that of the 3DMCO and 4DMCO plans. The 4DMCO plans did not always achieve OAR dose reductions compared to 3DMCO and 4DMCrenorm plans. CONCLUSION: This study indicates that 3DMCO with 2 mm margins for organ deformations may be inadequate for Cyberknife-based lung stereotactic body radiotherapy (SBRT). Renormalizing the 4DMCrecal plans could produce degraded dose conformity and increased OAR doses; 4DMCO can resolve this problem.
Authors: Xing-Qi Lu; Lakshmi Narayan Shanmugham; Anand Mahadevan; Elena Nedea; Mary Ann Stevenson; Irving Kaplan; Eric T Wong; Salvatore La Rosa; Frank Wang; Stuart M Berman Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-01 Impact factor: 7.038
Authors: Noëlle C van der Voort van Zyp; Bronno van der Holt; Robertus J van Klaveren; Peter Pattynama; Alexander Maat; Joost J Nuyttens Journal: Lung Cancer Date: 2010-01-08 Impact factor: 5.705
Authors: Viola J Chen; Eric Oermann; Saloomeh Vahdat; Jennifer Rabin; Simeng Suy; Xia Yu; Sean P Collins; Deepa Subramaniam; Filip Banovac; Eric Anderson; Brian T Collins Journal: Front Oncol Date: 2012-02-01 Impact factor: 6.244
Authors: Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck Journal: Strahlenther Onkol Date: 2017-09-05 Impact factor: 3.621
Authors: Susanne Temming; Martin Kocher; Erich Stoelben; Lars Hagmeyer; De-Hua Chang; Konrad Frank; Khosro Hekmat; Juergen Wolf; Wolfgang W Baus; Robert Semrau; Christian Baues; S Marnitz Journal: Strahlenther Onkol Date: 2017-08-15 Impact factor: 3.621
Authors: Oliver Blanck; Svenja Ipsen; Mark K Chan; Ralf Bauer; Matthias Kerl; Peter Hunold; Volkmar Jacobi; Ralf Bruder; Achim Schweikard; Dirk Rades; Thomas J Vogl; Peter Kleine; Frank Bode; Jürgen Dunst Journal: Cureus Date: 2016-07-20
Authors: Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck Journal: Front Oncol Date: 2018-05-17 Impact factor: 6.244